New catheter aims to save limbs when all else fails
NCT ID NCT06311773
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a device called the Boomerang Catheter in 120 people with chronic limb-threatening ischemia (CLTI), a severe condition where blocked leg arteries can lead to amputation. The catheter creates a connection between a vein and an artery to reroute blood around the blockage. The main goal is to see if this procedure helps patients avoid amputation or death within 6 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Boomerang Catheter
What this could lead to
If successful, this device could offer a new way to save limbs and improve survival for people with severe leg artery blockages who have no other treatment options.
What could go wrong
This is an early-stage trial with only 120 participants and no comparison group, so results may not apply to everyone. Risks include procedural complications like bleeding or infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LIMB-THREATENING ISCHEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Advanced Vascular Centers
Tigard, Oregon, 97223, United States
-
American Endovascular and Amputation Prevention
West Orange, New Jersey, 07052, United States
-
Cardiovascular Institute of the South
Houma, Louisiana, 70360, United States
-
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
EndoVascular Consultants
Wilmington, Delaware, 19805, United States
-
First Coast Cardiovascular Institute
Jacksonville, Florida, 32256, United States
-
HOPE Vascular and Podiatry
Houston, Texas, 77054, United States
-
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Olive View-UCLA Medical Center
Sylmar, California, 91342, United States
-
PIH Whittier Hospital
Whittier, California, 90602, United States
-
Penn Medicine
Philadelphia, Pennsylvania, 19104, United States
-
Rush University Medical Center
Chicago, Illinois, 60612, United States
-
Sunrise Vascular
Murphy, North Carolina, 28906, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75235, United States
-
University of Washington Medicine
Seattle, Washington, 98133, United States
-
VIC Vascular Institute
Chattanooga, Tennessee, 37421, United States
-
Vascular Institute at AMI
Galloway, New Jersey, 08205, United States
-
Weill Cornell Medical Center
New York, New York, 10065, United States